| T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis M Oriano, A Gramegna, F Amati, A D’Adda, M Gaffuri, M Contoli, F Bindo, ... Biomedicines 9 (7), 772, 2021 | 33 | 2021 |
| Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p. Phe508del mutation A Gramegna, M Contarini, F Bindo, S Aliberti, F Blasi Current Opinion in Pharmacology 57, 81-88, 2021 | 20 | 2021 |
| Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients F Galli, F Bindo, A Motos, L Fernández-Barat, E Barbeta, A Gabarrús, ... Intensive care medicine 49 (8), 934-945, 2023 | 10 | 2023 |
| Lung recruitability of COVID-19 pneumonia in patients undergoing helmet CPAP F Amati, S Aliberti, S Misuraca, E Simonetta, F Bindo, A Vigni, L Bassi, ... Archivos de bronconeumologia 57, 92, 2021 | 10 | 2021 |
| Identify drug-resistant pathogens in patients with community-acquired pneumonia F Amati, F Bindo, A Stainer, A Gramegna, M Mantero, M Nigro, L Bussini, ... Advances in Respiratory Medicine 91 (3), 224-238, 2023 | 5 | 2023 |
| Respiratory failure: a patient's perspective and clinical cases F Amati, A Vigni, S Misuraca, F Bindo, A Gramegna, A Voza, F Blasi, ... ERS Monograph, 1-13, 2021 | 1 | 2021 |
| Procalcitonin to rule out early bacterial coinfection in COVID-19 critically ill patients F Galli, F Bindo, A Motos, L Fernandez-Barat, E Barbeta, S Misuraca, ... European Respiratory Journal 62 (suppl 67), 2023 | | 2023 |
| Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia A Francesco, F Bindo, S Anna, A Gramegna, M Mantero, N Mattia, B Linda, ... ADVANCES IN RESPIRATORY MEDICINE 91 (3), 224-238, 2023 | | 2023 |
| Reclutamiento alveolar en la neumonía por COVID-19 de pacientes tratados con sistema helmet-CPAP F Amati, S Aliberti, S Misuraca, E Simonetta, F Bindo, A Vigni, L Bassi, ... Archivos de Bronconeumología 57 (Supl. 1), 92-94, 2021 | | 2021 |
